The Pyrroloquinoline Quinone (PQQ) is a quinone molecule that is redox active and has important health consequences for people. Several preclinical studies reveal the anticancer property of PQQ molecule by different molecular pathways. but there is a lack of clinical studies evaluating this drug in oncology. Clinical investigations have only investigated PQQ as a dietary supplement, disodium salt. The known safety profile and availability of standardized formulations provide the opportunity to advance PQQ into translational research in cancer. Future initiatives will involve testing in animal tumor models, analyzing possible synergistic effects with existing medicines, improving formulations to boost absorption, and discovering biomarkers to help patient selection.
Sen et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: